Researchers established a genetically engineered mouse model of BrafV600E-driven melanoma minimal residual disease, wherein genetic BrafV600E extinction led to strong but incomplete tumor regression.
[Cancer Immunology Research]
Home Newsletters Immune Regulation News Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma
